Accenture backs Ryght AI to speed site selection, feasibility, and enrollment with agentic AI
Accenture Ventures has invested in Ryght AI, a platform focused on modernizing how clinical research is designed and executed. The goal: help sponsors and CROs bring new treatments to patients faster by combining agentic AI with enterprise-grade delivery.
The timing makes sense. Clinical trials are getting more complex, while site selection and patient enrollment continue to slow studies. Manual feasibility and site startup can add weeks or months to timelines, straining budgets and delaying access to promising therapies.
What Ryght AI brings
Ryght AI's AI Site Twin platform builds dynamic digital replicas of clinical research sites. These models capture historical performance, patient demographics, and operational signals in near real-time.
- Find sites that meet protocol and regulatory criteria with higher confidence
- Forecast enrollment with better signal on screen failure risk and throughput
- Streamline site activation with workflow automation and data-driven prioritization
Why Accenture matters here
This collaboration pairs Ryght AI's domain-specific agentic AI with Accenture's industry, technology, and data-engineering expertise. That combination is set to accelerate three high-impact steps in drug development:
- Trial feasibility
- Site selection
- Patient recruitment
"Generative and agentic AI are transforming the foundation of clinical research," said Petra Jantzer, PhD, Senior Managing Director and Global Lead of Life Sciences at Accenture. "With our investment in Ryght AI, we're giving our life sciences clients the ability to fully leverage operational and scientific data and bring life-changing therapies to market faster, more efficiently, and with greater precision."
"This partnership allows Ryght AI to extend the impact and adoption of our technology to a global scale. Together, we can help life science companies reimagine how clinical trials are planned, launched, and managed-accelerating the path from discovery to treatment," said Simon Arkell, CEO at Ryght AI.
What this means for R&D, clinical ops, and data teams
- Data readiness: Consolidate site performance history, investigator profiles, and patient population data (EHR, claims, registries) with clear provenance and refresh cadence.
- Workflow integration: Tie AI Site Twin insights into feasibility, budgeting, contracting, and activation workflows so recommendations turn into action.
- Governance: Maintain auditability, bias checks, and access controls. Ryght AI's platform is SOC Type 2-compliant; align this with your internal controls.
- Metrics that matter: Track enrollment rate, screen failure rate, startup cycle time, protocol deviation rate, and forecast accuracy to quantify lift.
Context and trajectory
Terms of the investment were not disclosed. This move follows Accenture's recent investments in biotech and AI-driven research companies such as 1910 Genetics, Turbine, and Earli-each focused on compressing discovery and development timelines.
About the companies
Accenture: A global professional services company helping enterprises build their digital core and apply AI at scale across strategy, consulting, technology, operations, Song, and Industry X. Learn more at accenture.com.
Ryght AI: An intelligent platform built around AI Site Twins-dynamic models representing clinical sites worldwide. It helps sponsors and CROs speed study startup via faster site selection and streamlined feasibility, using generative and agentic AI and real-time collaboration between sponsors, CROs, and sites. Details at ryght.ai.
If your team is upskilling in agentic AI
Explore practical, role-based training to bring AI into clinical and R&D workflows: AI courses by job.
Your membership also unlocks:
